About this Research Topic
Autoimmune diseases threaten public health and affect people's lives. A deep understanding of the features of autoimmune diseases can effectively assist in clinical practice.
Recent studies showed that the etiology and pathogenesis of autoimmune diseases are complex, such as genetic factors, malfunction of the body's immune system, and the influence of age, gender, and endocrine. It was shown that negative immune checkpoints such as CTLA-4/VISTA/PD-1/PD-L1/B7-H3/B7-H4 play a major role in the development and progression of autoimmune diseases, and that agitation of these negative immune checkpoints may also alleviate the effects of autoimmune diseases. Therefore, clarifying how negative immune checkpoints function and the mechanisms involved can provide a new idea for the clinical treatment of diseases.
This Research Topic will focus on the mechanisms underlying the role of negative immune checkpoints in Systemic Lupus Erythematosus and Rheumatoid Arthritis, such as identifying possible target cells and molecular pathways and finding possible negative immune checkpoint agonists. We hope that this topic will provide clinicians with cutting-edge insights into the diagnosis and treatment of autoimmune diseases, explore the mechanisms of negative immune checkpoints in treating autoimmune diseases, provide molecules that may alleviate the symptoms, and ultimately facilitate the clinical treatment of autoimmune diseases.
In this Research Topic, we welcome the submissions of Original Research, Reviews, Mini-Reviews, Methods, and Brief Research Reports focusing on, but not limited to the following subtopics:
① Mechanism of the role of immune checkpoint PD-1 in SLE;
② Mechanism of the role of immune checkpoint VISTA in SLE;
③ Study of the effect of PD-1/VISTA agonists in the treatment of SLE;
④ PD-1/VISTA agonists in the treatment of SLE may affect IFN-α release by acting on pDC/IMM, thereby achieving disease relief;
⑤ PD-1/VISTA agonists achieve disease relief by affecting the interaction between T cells and antigen-presenting cells;
⑥ PD-1/VISTA agonists in the treatment of SLE may act by acting on the Non-canonical NF-KB pathway to achieve disease relief;
⑦ Basic research of immunological diagnostic or therapeutic immune targets or biomarkers in RA;
⑧ Recent advances or novel techniques in the identification, characterization, and validation of immune targets or biomarkers that are associated with RA.
Recent studies showed that the etiology and pathogenesis of autoimmune diseases are complex, such as genetic factors, malfunction of the body's immune system, and the influence of age, gender, and endocrine. It was shown that negative immune checkpoints such as CTLA-4/VISTA/PD-1/PD-L1/B7-H3/B7-H4 play a major role in the development and progression of autoimmune diseases, and that agitation of these negative immune checkpoints may also alleviate the effects of autoimmune diseases. Therefore, clarifying how negative immune checkpoints function and the mechanisms involved can provide a new idea for the clinical treatment of diseases.
This Research Topic will focus on the mechanisms underlying the role of negative immune checkpoints in Systemic Lupus Erythematosus and Rheumatoid Arthritis, such as identifying possible target cells and molecular pathways and finding possible negative immune checkpoint agonists. We hope that this topic will provide clinicians with cutting-edge insights into the diagnosis and treatment of autoimmune diseases, explore the mechanisms of negative immune checkpoints in treating autoimmune diseases, provide molecules that may alleviate the symptoms, and ultimately facilitate the clinical treatment of autoimmune diseases.
In this Research Topic, we welcome the submissions of Original Research, Reviews, Mini-Reviews, Methods, and Brief Research Reports focusing on, but not limited to the following subtopics:
① Mechanism of the role of immune checkpoint PD-1 in SLE;
② Mechanism of the role of immune checkpoint VISTA in SLE;
③ Study of the effect of PD-1/VISTA agonists in the treatment of SLE;
④ PD-1/VISTA agonists in the treatment of SLE may affect IFN-α release by acting on pDC/IMM, thereby achieving disease relief;
⑤ PD-1/VISTA agonists achieve disease relief by affecting the interaction between T cells and antigen-presenting cells;
⑥ PD-1/VISTA agonists in the treatment of SLE may act by acting on the Non-canonical NF-KB pathway to achieve disease relief;
⑦ Basic research of immunological diagnostic or therapeutic immune targets or biomarkers in RA;
⑧ Recent advances or novel techniques in the identification, characterization, and validation of immune targets or biomarkers that are associated with RA.
Keywords: Negative Immune Checkpoint, Treatment, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
